Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Core Insights - Purple Biotech Ltd. is set to present new preclinical data from its CAPTN-3 platform at the ESMO-IO 2025 Annual Congress, highlighting its potential in treating resistant cancers [1][3]. Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance [5]. - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [5]. CAPTN-3 Platform - The CAPTN-3 platform can produce tri-specific antibodies that engage T cells and NK cells while binding to tumor-associated antigens, demonstrating strong synergy in preclinical studies [3]. - The platform's unique design allows for localized immune responses within the tumor microenvironment, potentially increasing the therapeutic window for patients [5]. Lead Program IM1240 - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with various solid tumors and poor clinical outcomes [5]. - New data from IM1240 will be showcased in multiple PD-1 resistant models at the upcoming congress [3]. Other Pipeline Products - CM24 is a humanized monoclonal antibody that blocks CEACAM1, a target for multiple cancer indications, and has shown improvement in a Phase 2 study for pancreatic ductal adenocarcinoma [5]. - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, with demonstrated anti-tumor activity in combination with cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck [5]. Presentation Details - The presentation at the ESMO-IO 2025 Annual Congress will be led by Dr. Hadas Reuveni, focusing on the unique design of the CAPTN-3 platform [7].